Chronic back pain frequently stems from degenerative disc disease—loss of hydration and structural integrity in intervertebral discs—compounded by facet joint arthritis and paraspinal muscle atrophy.
Chronic back pain frequently stems from degenerative disc disease—loss of hydration and structural integrity in intervertebral discs—compounded by facet joint arthritis and paraspinal muscle atrophy. Stem cell strategies target the nucleus pulposus (disc centre), where placental mesenchymal stem cells (MSCs) may regenerate proteoglycan matrix and restore biomechanical function. Exosomes derived from stem cells penetrate the avascular disc environment and deliver anti-inflammatory proteins that suppress catabolic pathways. Unlike surgical fusion, which immobilises segments, cell-based approaches aim to restore disc biology whilst preserving motion. MSCs also modulate neuropathic pain via immune suppression, addressing pain signalling independent of structural restoration. Thirty-five registered trials globally investigate disc regeneration and pain outcomes; two actively recruit new participants.
| 指示性成本 · 保加利亚 (EU) | €3,000–€8,000 |
|---|---|
| 全球市场成本范围 | €4,600–€13,800 (dvcstem.com) |
| 研究的主要细胞类型 | MSCs from Amniotic Membrane, Exosomes |
| 批准状态 | 研究性 |
| 注册的临床试验 (ClinicalTrials.gov) | 35 · 2 recruiting now |
For the clinic's own description, see our partner clinic Stem Plus.
Published trials of intradiscal placental MSC injection demonstrate pain reduction (VAS or Oswestry scales) in 50–65% of participants over 6–12 months. Discography MRI findings show improved hydration signals in 30–50% of treated discs, interpreted as proteoglycan restoration, though correlation with pain outcomes is inconsistent. One phase II trial (67 patients) reported sustained pain relief at 24-month follow-up in 55% of injected discs. Exosome intra-discal delivery is emerging with small proof-of-concept studies showing reduced inflammatory biomarkers in disc fluid post-injection. Comparative data versus sham injection remain limited; most positive evidence derives from open-label or non-blinded designs.
Depending on assessment, a Back & Disc Degeneration protocol may draw on:
Intradiscal stem cell injection costs €4,500–7,000 per disc in European centres. Percutaneous or fluoroscopy-guided approaches command €5,000–6,500; minimally invasive endoscopic delivery may cost €6,500–7,500. Exosome-based disc therapy is priced similarly (€5,000–7,000). Most patients with multilevel disease require 2–3 treated discs, escalating total cost to €10,000–20,000. Few insurance schemes reimburse disc regeneration therapy; most classify as investigational. Out-of-pocket expense is expected, though some European countries (Spain, Portugal) offer selective reimbursement under medical necessity criteria.
Indicative EU treatment cost is €3,000–€8,000 versus roughly €15,000–35,000 in the US or Germany. Build your real all-in total with the cost calculator, see the Back & Disc Degeneration cost-by-country breakdown, or compare the best countries for Back & Disc Degeneration →
Before booking, check safety & regulation, the recovery climate, 您是否可能是候选人, and which cell type fits Back & Disc Degeneration.
完整脊柱和椎间盘退行性变常见问题 → · 脊柱和椎间盘退行性变成本分解 →
We link primary regulators, registries and peer-reviewed research so you can verify everything yourself — plus the treating clinic's own materials.
Useful tools & guides: 我是候选人吗？ · 哪种细胞类型？ · Types of clinics & best countries · 成本计算器
由 StemCellAtlas 的编辑团队进行医学审查，与Kiian Nadiia, MD, PhD (Paediatric Neurologist · Medical Director, CSM Clinic Network · 12+ yrs in Autism Spectrum Disorders) 合作诊所 Stem Plus（索菲亚）的，根据 ISSCR、FDA 和 EMA 指南。 Educational information, not medical advice; figures indicative.
位于欧盟核心的 GMP 认证再生医学诊所——费用 3,000–8,000 欧元起，仅为美国或德国价格的一小部分。为来自 50 多个国家的国际患者提供个性化方案。
免费医疗评估